Bellicum Pharmaceuticals Inc (BLCM)


Stock Price Forecast

June 30, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Bellicum Pharmaceuticals Inc chart...

About the Company

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

CEO

Richard Fair

Exchange

NASDAQ

Website

http://www.bellicum.com/

$31M

Total Revenue

13

Employees

$3M

Market Capitalization

-0.45

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BLCM News

Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

11mon ago, source: Hosted on MSN

NantHealth, Inc. (NASDAQ: NH ... get started now. This article Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket originally appeared on ...

Bellicum Pharmaceuticals Inc BLCM

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bellicum Pharmaceuticals Inc BPXA

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Why Blue Bird Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket

11mon ago, source: Hosted on MSN

VirnetX recently announced a partnership with Samsung. Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares dropped 14.7% to $0.6824 in pre-market trading. A 13D filing recently showed Baker Bros.

Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

29d ago, source: ADVFN

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at ...

Remeditex Ventures LLC's Net Worth

22d ago, source: Benzinga.com

Inc., Menlo Therapeutics Inc., and BELLICUM PHARMACEUTICALS, INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to ...

CRVS Corvus Pharmaceuticals, Inc.

2d ago, source: Seeking Alpha

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...

NRBO NeuroBo Pharmaceuticals, Inc.

1d ago, source: Seeking Alpha

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 ...

MDJM Stock (NASDAQ:MDJH), Quotes and News Summary

8d ago, source: Benzinga.com

Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced ...

Madrigal Pharmaceuticals, Inc. (MDGL)

2d ago, source: Yahoo Finance

CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday ...

Vanda Pharmaceuticals Inc.

3d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Corvus Pharmaceuticals, Inc. (CRVS)

2d ago, source: Yahoo Finance

Tesla said it would "accelerate" the launch of new models next year, including lower-cost cars, countering reports earlier this month it had scraped those plans. Texas Instruments (TXN) reported ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...